abbotts thai pact may augur pricing shift abbott laboratories has backed away from a confrontation with the thai government over patent protection for a popular aids treatment a concession that could embolden other developing countries pushing big drug makers to lower the price of their products abbott is offering to sell the latest version of its aids drug kaletra in thailand at a discounted rate according to miles d white abbotts chief executive the move reverses abbotts decision in february to withhold the new form of kaletra called aluvia in some countries from thailand following a thai government announcement it would allow sales of generic versions of the drug and other branded medicines to cut patients costs "in this particular case in the name of access for patients we offered to resubmit aluvia at our new price which is lower than any generic provided they wouldnt issue a compulsory license " mr white said he said the initial decision was driven by "concern that compulsory licensing would be abused ever more widely using hiv as an excuse " jennifer smoter a spokeswoman for abbott said thailands health ministry has expressed interest in the offer but a resolution hasnt been reached abbotts move doesnt affect its decision to withhold six other drugs from thailand abbotts turnabout could crimp growth of global drug makers which rely on emerging markets to compensate for slowing growth in home markets gustav ando an analyst for global insight an economic forecasting firm in waltham mass said "if one country does it any country can do it its not going to stop there " abbott of abbott park ill in february refused to sell the country seven of its newest drugs the move appeared to backfire prompting consumer boycotts in thailand bringing human rights advocates out in support of thailands policy and provoking protests from some abbott shareholders who argued abbott should sell its latest drugs in thailand thailand generated about &# million a year in sales for abbott said a person familiar with the companys sales in backing down abbott is joining merck &amp co and sanofi aventis sa which already have cut the prices of their aids and heart disease drugs in the hope of dissuading thailand from switching to less expensive alternatives thailand still could choose to import generic drugs to replace abbotts however just as it is now using generic versions of mercks aids drug efavirenz despite mercks own move to lower prices big drug companies have been pushing sales in emerging markets like thailand in part because of a backlash against expensive brand name drugs in the u s and other western markets merck expects revenue in emerging markets to double by to more than &# billion a year abbotts international pharmaceutical sales totaled &# billion in the first quarter of this year nearly as much as its &# billion in u s sales in abbotts total sales in the u s dropped to &# billion while the companys international revenue rose nearly to &# billion 
